Financial Performance - The company's operating revenue for Q1 2023 was ¥233,350,600.29, representing a 6.25% increase compared to ¥219,622,410.85 in the same period last year[4] - Net profit attributable to shareholders was ¥33,794,308.43, an increase of 85.09% from ¥18,258,381.70 year-on-year[4] - Basic earnings per share rose to ¥0.31, up 34.78% from ¥0.23 in the same period last year[4] - Net profit for Q1 2023 reached ¥33,805,783.03, up 68.5% from ¥20,060,843.88 in the same period last year[19] - Operating profit increased to ¥38,443,089.91, a rise of 63.3% compared to ¥23,547,646.61 in Q1 2022[19] - Total comprehensive income for Q1 2023 was ¥33,805,783.03, compared to ¥20,060,843.88 in the previous year, marking a 68.5% increase[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.31, up from ¥0.23 in Q1 2022[20] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥43,097,793.56, a significant increase of 844.55% compared to a negative cash flow of -¥5,788,404.68 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥43,097,793.56, a significant improvement from a negative cash flow of ¥5,788,404.68 in Q1 2022[21] - The net increase in cash and cash equivalents was ¥22,466,667.14, a 279.40% increase compared to a decrease of -¥12,523,509.37 in the previous year[9] - Cash and cash equivalents at the end of Q1 2023 totaled ¥273,129,358.57, an increase from ¥127,772,327.87 at the end of Q1 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,654,149,532.15, a slight increase of 0.32% from ¥1,648,907,339.15 at the end of the previous year[4] - Total assets as of March 31, 2023, amounted to CNY 1,654,149,532.15, a slight increase from CNY 1,648,907,339.15 at the beginning of the year[14] - Total liabilities decreased from CNY 303,585,791.80 to CNY 273,736,446.48, indicating a reduction of about 9.8%[16] - The company's total equity increased from CNY 1,345,321,547.35 to CNY 1,380,413,085.67, representing a growth of approximately 2.6%[16] Research and Development - Research and development expenses increased by 36.53% to ¥7,999,391.16, aimed at enhancing product competitiveness[8] - Research and development expenses rose to ¥7,999,391.16, up 36.5% from ¥5,859,191.13 year-over-year[18] - The company is actively engaged in research and development of new products and technologies, although specific details were not disclosed in the report[12] Shareholder Information - The number of common shareholders at the end of the reporting period was 9,691, with the largest shareholder holding 52.78% of the shares[11] - The company has a total of 57,000,000 shares held by the largest shareholder, 联盛化学集团, which represents a significant portion of the ownership structure[11] Inventory and Receivables - Inventory levels decreased from CNY 107,264,309.16 to CNY 77,704,492.65, a decline of about 27.5%[15] - Accounts receivable rose from CNY 130,926,297.97 to CNY 159,672,876.01, an increase of approximately 21.9%[14] Financial Expenses and Taxation - The company reported a significant decrease in financial expenses, with a net income of -¥2,476,599.69, compared to ¥1,865,161.69 in the same period last year, due to increased interest income from raised funds[8] - The company experienced a 152.07% increase in taxes and surcharges, amounting to ¥1,131,233.33, attributed to higher revenue[8] Operating Costs - Total operating costs decreased to ¥194,039,600.39 from ¥194,983,743.05, reflecting a reduction of 0.5%[18]
联盛化学(301212) - 2023 Q1 - 季度财报